Immune & Resilience.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid thymic peptide — the endogenous form is secreted by thymic epithelial cells to direct T-cell maturation. Clinically, it works by binding Toll-like receptors on dendritic cell subsets, rebalancing pro-inflammatory and anti-inflammatory cytokine output rather than simply boosting immunity. This makes it an immunomodulator, not an immunostimulant: it lifts suppressed immune function while reducing overactive inflammatory signalling. It also promotes NK cell and CD4+/CD8+ T-cell function directly. Marketed as ZADAXIN, it is approved in 37 countries for chronic hepatitis B, hepatitis C, HIV, sepsis, and oncology immunotherapy support — the most extensively validated immune peptide in this catalogue by regulatory standard.

Best for · Age-related immune decline, recurrent infections, post-illness recovery, chronic viral conditions (EBV, CMV, HBV, HCV), cancer immunotherapy support, and anyone who needs evidence-grounded immune modulation rather than non-specific stimulation.

Thymalin is a polypeptide complex derived from the thymus gland, developed within the Khavinson MMA-Kirov bioregulator programme — the same Russian gerontology research lineage that produced Epitalon. Where Thymosin Alpha-1 targets cytokine balance via TLR signalling, Thymalin operates at a broader cellular level: restoring hematopoietic function, regulating gene expression in lymphocytes, and supporting the thymic architecture that produces T-cells over time. It is typically administered in short 5–10 day pulse courses rather than continuously, making it a natural complement to Tα1's ongoing immunomodulation. Used in Russian clinical protocols for cancer immunotherapy support, age-related immune decline, and post-infectious immune reconstitution.

Best for · Layering onto Thymosin Alpha-1 for broader thymic restoration; seasonal immune maintenance via pulse cycles; users who want Russian bioregulator heritage alongside Western RCT validation.

Thymogen is a synthetic Glu-Trp dipeptide derived from the Khavinson thymic bioregulator lineage — one of the smallest peptide structures in the immune category, yet functionally targeted. Its primary mechanism is modulation of T-cell function at mucosal and respiratory immune surfaces: the epithelial interfaces where airborne and ingested pathogens make first contact. It acts as a precision regulator rather than a broad-spectrum stimulator, calming overactive immune branches while supporting lagging ones at the mucosal level. Often paired with Thymalin in Russian clinical protocols for respiratory infections, chronic bronchitis, and mucosal immune vulnerability. Its distinct mechanism — mucosal T-cell regulation — gives it a cellular target neither Tα1 nor Thymalin covers directly.

Best for · Respiratory immune vulnerability, recurrent upper respiratory infections, mucosal inflammation, and completing the three-axis thymic restoration protocol alongside Tα1 and Thymalin.

BPC oral spray delivers BPC-157 directly to the mucosal surface of the gastrointestinal tract — the body's largest immune surface, housing approximately 70% of immune cells in the gut-associated lymphoid tissue (GALT). The mechanism here is the gut-immune axis: BPC-157 promotes mucosal healing, reduces intestinal permeability, suppresses local inflammatory signalling, and supports the tissue repair pathways in the gut lining that maintain immune homeostasis. When gut dysbiosis, antibiotic damage, or chronic inflammation has impaired the intestinal barrier, immune dysregulation can originate there even when thymic function is intact. Oral spray delivers BPC locally where it is needed most, making it mechanistically distinct from systemic BPC-157 injection.

Best for · Gut-driven immune dysregulation, IBD-adjacent patterns, post-antibiotic immune recovery, chronic mucosal inflammation, and anyone whose immune dysfunction has a gut-permeability component alongside thymic decline.

Systemic BPC-157 — administered subcutaneously or intramuscularly — works via a broader gut-immune cross-talk mechanism than oral spray. While oral spray concentrates BPC activity at the mucosal surface, systemic administration promotes vascular repair, modulates nitric oxide signalling, and supports the healing of gut and connective tissue systemically. The gut-immune axis connection remains: BPC-157's anti-inflammatory and tissue-repair activity reduces systemic inflammatory load originating from gut-barrier dysfunction, supporting immune regulation indirectly. Used here as the systemic complement to BPC-spray for users with more extensive gut-tissue involvement or systemic inflammatory burden with a gut driver.

Best for · Systemic gut-immune support where oral spray alone is insufficient; users with broader gut-tissue involvement, post-surgical gut healing, or systemic inflammation with a gut-permeability component.